An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Platzbecker, Uwe
Symeonidis, Argiris
Goede, Jeroen Simon
Guerci-Bresler, Agnes
Delforge, Michel
Oliva, Esther Natalie
Mayer, Jiri
Badre, Sejal
Mehta, Bhakti
Brandao, Cisio De Oliveira
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4271
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Oliva, Esther N.
    Goede, Jeroen S.
    Delforge, Michel
    Mayer, Jiri
    Slama, Borhane
    Badre, Sejal
    Gasal, Eduard
    Mehta, Bhakti
    Franklin, Janet
    [J]. BLOOD, 2016, 128 (22)
  • [2] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
  • [3] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S29 - S30
  • [4] Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response
    Villegas, A.
    Arrizabalaga, B.
    Fernandez-Lago, C.
    Castro, M.
    Mayans, J. R.
    Gonzalez-Porras, J. R.
    Duarte, R. F.
    Remacha, A. F.
    Luno, E.
    Gasquet, J. A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 951 - 960
  • [5] Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study
    Villegas, Ana
    Arrizabalaga, B.
    Fernandez-lago, C.
    Mouzo, M.
    Mayans, Jr
    Gonalez-Porras, Jr
    Duarte, Rafael
    Remacha, Angel Francisco
    Luno, Elisa
    Gasquet, J. A.
    [J]. BLOOD, 2008, 112 (11) : 1184 - 1184
  • [6] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    [J]. BLOOD, 2014, 124 (21)
  • [7] Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2014, 124 (21)
  • [8] Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    Stasi, R
    Abruzzese, E
    Lanzetta, G
    Terzoli, E
    Amadori, S
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (12) : 1921 - 1927
  • [9] Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation
    Daher, May
    Lopez, Juliana Elisa Hidalgo
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Pemmaraju, Naveen
    Borthakur, Gautam
    Kadia, Tapan M.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine P.
    Reyes, Steven R.
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2016, 128 (22)
  • [10] Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Wang, Xuemei
    Abruzzo, Lynne V.
    Cornelison, A. Megan
    O'Brien, Susan
    Ravandi, Farhad
    Kadia, Tapan
    Borthakur, Gautam
    Estrov, Zeev
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2011, 118 (21) : 1624 - 1624
12345